» Articles » PMID: 38561447

Clinicopathological Characteristics and Prognosis in Patients with Monoclonal Gammopathy and Renal Damage in Central China: a Multicenter Retrospective Cohort Study

Overview
Journal Sci Rep
Specialty Science
Date 2024 Apr 1
PMID 38561447
Authors
Affiliations
Soon will be listed here.
Abstract

Renal involvement is common in monoclonal gammopathy (MG); however, the same patient may have both MG and non-paraprotein-associated renal damage. Accordingly, distinguishing the cause of renal damage is necessary because of the different clinical characteristics and associated treatments. In this multicenter retrospective cohort study, we described the clinicopathological characteristics and prognosis of 703 patients with MG and renal damage in central China. Patients were classified as having MG of renal significance (MGRS), MG of undetermined significance (MGUS), or hematological malignancy. 260 (36.98%), 259 (36.84%), and 184 (26.17%) had MGRS, MGUS, and hematological malignancies, respectively. Amyloidosis was the leading pattern of MGRS (74.23%), followed by thrombotic microangiopathy (8.85%) and monoclonal immunoglobulin deposition disease (8.46%). Membranous nephropathy was the leading diagnosis of MGUS (39.38%). Renal pathological findings of patients with hematological malignancies included paraprotein-associated lesions (84.78%) and non-paraprotein-associated lesions (15.22%). The presence of nephrotic syndrome and an abnormal free light chain (FLC) ratio were independently associated with MGRS. The overall survival was better in patients with MGUS than in those with MGRS or hematological malignancies.

Citing Articles

Monoclonal Gammopathy of Clinical Significance (MGCS) and Related Disorders: A Review and the Role of Imaging.

El Sadaney A, Dutta A, Cook J, Baffour F Diagnostics (Basel). 2024; 14(17).

PMID: 39272692 PMC: 11394483. DOI: 10.3390/diagnostics14171907.

References
1.
Gertz M . Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management. Am J Hematol. 2023; 98(2):348-358. PMC: 10249724. DOI: 10.1002/ajh.26796. View

2.
Kyle R, Rajkumar S . Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2008; 23(1):3-9. PMC: 2627786. DOI: 10.1038/leu.2008.291. View

3.
Yui J, Garceau D, Jhaveri K, Wanchoo R, Bijol V, Glezerman I . Monoclonal gammopathy-associated thrombotic microangiopathy. Am J Hematol. 2019; 94(10):E250-E253. PMC: 7508258. DOI: 10.1002/ajh.25569. View

4.
Ravindran A, Go R, Fervenza F, Sethi S . Thrombotic microangiopathy associated with monoclonal gammopathy. Kidney Int. 2016; 91(3):691-698. DOI: 10.1016/j.kint.2016.09.045. View

5.
Tang X, Wan F, Yu J, Li X, Yang R, Zhu B . Clinicopathological characteristics of patients with paraproteinemia and renal damage. Eur J Med Res. 2021; 26(1):68. PMC: 8255003. DOI: 10.1186/s40001-021-00538-2. View